The global ophthalmic therapeutics/drug market is predicted to value USD 35.7 billion by 2025, according to a research report offered by Grand View Research, Inc. Growing need for safer and more effective drugs for the treatment of different types of eye disorders, such as glaucoma and dry eye, is anticipated to propel the demand for advanced ophthalmic therapeutics/drugs. High prevalence of various eye disorders such as macular degeneration, presbyopia, and diabetic retinopathy are also likely to stimulate the demand for ophthalmic therapeutics and drugs. Leading companies investing in R&D to fulfill the rising demand for highly effective and safer products
For instance, Aerie Pharmaceuticals recently introduced Rhopressa to reduce elevated intraocular pressure in patients suffering from open-angle glaucoma or ocular hypertension. This product was approved by the US Food and Drug Administration (FDA) in December 2017. The company is expected to be working on the development of another product named Roclatan, a combination of Rhopressa and widely prescribed PGA (prostaglandin analog) Latanoprost. Currently, this product is under testing phase 3. If this product clears through testing, the company would be filing a New Drug Application (NDA) for its approval. If approved, the new product will be the first-ever glaucoma product to reduce intraocular pressure (IOP) through all known mechanisms.
For More Insight Click Here : https://www.grandviewresearch.com/industry-analysis/ophthalmic-therapeutics-drug-market/
The global ophthalmic therapeutics/drug market is estimated to witness a decent growth rate of 5.1 % during the forecast period (from 2018 to 2025). Increasing cases of various eye disorders as a result of rising geriatric population base are likely to stimulate the growth of the global market. Escalating demand for effective and safe agents to cure eye diseases can further impel the growth of this market. Moreover, rising number of public and private firms investing in R&D activities to develop effective drugs is also expected to support the market development in the next few years. Growing inclination toward combination therapies to treat several ophthalmic disorders can also foster growth in the coming years. Some of the leading companies offering safe and effective ophthalmic therapeutics/drugs are Santen Pharmaceutical Co., Ltd.; Pfizer Inc.; Novartis AG; Allergan; and Merck & Co., Inc.
Get Free Sample Report : https://www.grandviewresearch.com/industry-analysis/ophthalmic-therapeutics-drug-market/request
For instance, Aerie Pharmaceuticals recently introduced Rhopressa to reduce elevated intraocular pressure in patients suffering from open-angle glaucoma or ocular hypertension. This product was approved by the US Food and Drug Administration (FDA) in December 2017. The company is expected to be working on the development of another product named Roclatan, a combination of Rhopressa and widely prescribed PGA (prostaglandin analog) Latanoprost. Currently, this product is under testing phase 3. If this product clears through testing, the company would be filing a New Drug Application (NDA) for its approval. If approved, the new product will be the first-ever glaucoma product to reduce intraocular pressure (IOP) through all known mechanisms.
For More Insight Click Here : https://www.grandviewresearch.com/industry-analysis/ophthalmic-therapeutics-drug-market/
The global ophthalmic therapeutics/drug market is estimated to witness a decent growth rate of 5.1 % during the forecast period (from 2018 to 2025). Increasing cases of various eye disorders as a result of rising geriatric population base are likely to stimulate the growth of the global market. Escalating demand for effective and safe agents to cure eye diseases can further impel the growth of this market. Moreover, rising number of public and private firms investing in R&D activities to develop effective drugs is also expected to support the market development in the next few years. Growing inclination toward combination therapies to treat several ophthalmic disorders can also foster growth in the coming years. Some of the leading companies offering safe and effective ophthalmic therapeutics/drugs are Santen Pharmaceutical Co., Ltd.; Pfizer Inc.; Novartis AG; Allergan; and Merck & Co., Inc.
Get Free Sample Report : https://www.grandviewresearch.com/industry-analysis/ophthalmic-therapeutics-drug-market/request
ConversionConversion EmoticonEmoticon